Published in Nat Genet on October 01, 1995
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics (2004) 5.65
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol (2001) 2.27
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol (2004) 2.11
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol (2003) 1.81
FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci U S A (1996) 1.80
Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J (2001) 1.69
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer (1997) 1.65
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Renal cell carcinoma. Cancer Biomark (2010) 1.56
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43
Overcoming cellular senescence in human cancer pathogenesis. Genes Dev (1998) 1.36
Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol (1997) 1.36
High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol (1996) 1.32
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31
Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol (2000) 1.28
What we could do now: molecular pathology of bladder cancer. Mol Pathol (2001) 1.22
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene (2011) 1.21
Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia (2004) 1.20
Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol (2016) 1.20
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17
Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet (1999) 1.13
Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol (1997) 1.13
CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol (2001) 1.12
A novel approach for determining cancer genomic breakpoints in the presence of normal DNA. PLoS One (2007) 1.12
Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol (1997) 1.08
Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Res (2000) 1.07
Molecular biology of adenoid cystic carcinoma. Head Neck (2011) 1.07
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol (2001) 1.04
Chromosome 9 arm-specific telomere length and breast cancer risk. Carcinogenesis (2009) 1.03
Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. Cancer Ther (2007) 1.02
Chromosomal alterations in lung metastases of colorectal carcinomas: associations with tissue specific tumor dissemination. Clin Exp Metastasis (2006) 1.02
Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int J Cancer (2009) 1.02
Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol (1998) 1.01
Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol (2012) 1.00
A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids. Proc Natl Acad Sci U S A (1996) 0.99
Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. J Clin Pathol (2002) 0.99
Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer. Oncogene (2004) 0.99
Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol (2010) 0.96
DPC4 gene mutation in colitis associated neoplasia. Gut (1997) 0.96
Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol (1999) 0.96
Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet (1996) 0.96
Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol (1997) 0.93
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol (2001) 0.91
Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. Br J Cancer (2000) 0.91
Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics (2010) 0.91
p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest (2010) 0.91
High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer (1999) 0.90
Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels. PLoS One (2012) 0.90
TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo. PLoS One (2013) 0.87
P16 and p53 play distinct roles in different subtypes of breast cancer. PLoS One (2013) 0.86
Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. Hum Genomics (2012) 0.86
p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol (2000) 0.86
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer (2000) 0.85
Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res (2003) 0.85
Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J Mol Diagn (2011) 0.85
Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J Mol Diagn (2004) 0.85
Inhibition of Breast Tumor Cell Growth by Ectopic Expression of p16/INK4A Via Combined Effects of Cell Cycle Arrest, Senescence and Apoptotic Induction, and Angiogenesis Inhibition. J Cancer (2012) 0.83
The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer. Br J Cancer (1999) 0.83
Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am J Pathol (1996) 0.83
Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines. Br J Cancer (1999) 0.82
Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma. Int Forum Allergy Rhinol (2013) 0.81
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol (1997) 0.80
P16 Methylation as an Early Predictor for Cancer Development From Oral Epithelial Dysplasia: A Double-blind Multicentre Prospective Study. EBioMedicine (2015) 0.80
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer (2016) 0.79
Expression of p16/INK4a in posttransplantation lymphoproliferative disorders. Am J Pathol (2000) 0.79
p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol (2003) 0.79
Genome stability pathways in head and neck cancers. Int J Genomics (2013) 0.79
Epigenetic regulation of prostate cancer. Clin Epigenetics (2011) 0.79
Differences between oral cancer and cancers of the pharynx and larynx on a molecular level. Oncol Lett (2011) 0.78
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. Cancer Inform (2014) 0.78
Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer (2000) 0.77
Two distinct pathways of p16 gene inactivation in gallbladder cancer. World J Gastroenterol (2007) 0.77
Loss of p16INK4A expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected synovial sarcomas. Virchows Arch (2005) 0.77
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World J Urol (1997) 0.76
p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget (2016) 0.75
Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol (2016) 0.75
sCNAphase: using haplotype resolved read depth to genotype somatic copy number alterations from low cellularity aneuploid tumors. Nucleic Acids Res (2016) 0.75
Molecular-targeting therapies against quantitative abnormalities in gene expression with malignant tumors. Cancer Sci (2017) 0.75
Use of laser capture microdissection allows detection of loss of heterozygosity in chromosome 9p in breast cancer. Oncol Lett (2017) 0.75
Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development. Proc Natl Acad Sci U S A (2003) 0.75
Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer. Iran J Public Health (2014) 0.75
Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget (2016) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
An integrative model for the study of developmental competencies in minority children. Child Dev (1996) 9.23
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 6.29
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res (1997) 4.32
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Socioeconomic status, standard of living, and neurotic disorder. Lancet (1998) 3.80
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Scrambled exons. Cell (1991) 3.65
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Nucleotide sequence of the envelope gene of Friend murine leukemia virus. J Virol (1983) 3.41
Sequencing of the 16S-23S spacer in a ribosomal RNA operon of Zea mays chloroplast DNA reveals two split tRNA genes. Cell (1981) 3.40
Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res (2000) 3.37
Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation (1996) 3.34
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A (1993) 3.32
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Retracted Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (2005) 3.13
The candidate Wilms' tumour gene is involved in genitourinary development. Nature (1990) 3.13
Molecular analysis of the envelope gene and long terminal repeat of Friend mink cell focus-inducing virus: implications for the functions of these sequences. J Virol (1984) 3.09
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Factors influencing the development and amelioration of suicidal thoughts in the general population. Cohort study. Br J Psychiatry (2004) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother (1990) 2.91
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
A study of the classification of mental ill-health in general practice. Psychol Med (1985) 2.88
The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care (2001) 2.79
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
The twelve-month outcome of patients with neurotic illness in general practice. Psychol Med (1981) 2.74
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A (1994) 2.63
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Role of the p16 tumor suppressor gene in cancer. J Clin Oncol (1998) 2.51
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
How are nations trying to prevent suicide? An analysis of national suicide prevention strategies. Acta Psychiatr Scand (1997) 2.45
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (2000) 2.39
Minor psychiatric morbidity in employed young men and women and its contribution to sickness absence. Br J Ind Med (1985) 2.36
Minor psychiatric morbidity and the threat of redundancy in a professional group. Psychol Med (1982) 2.36
p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res (2001) 2.34
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol (1999) 2.34
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Isolation of genes from complex sources of mammalian genomic DNA using exon amplification. Nat Genet (1994) 2.33
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. N Engl J Med (1994) 2.22
A new human p53 homologue. Nat Med (1998) 2.21
Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst (2001) 2.18
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res (2001) 2.18